Y-Mabs Therapeutics Long Term Debt

Y-Mabs Therapeutics's long-term debt stands at $2.6M as of June 2025. That compares with $430K in the prior-year period — up 510.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Y-Mabs Therapeutics reported $2.6M in long-term debt versus $430K a year earlier — a 510.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $430K in the prior-year period — up 510.6% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Y-Mabs Therapeutics's long-term debt evolved across reporting periods, while the comparison chart places YMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Y-Mabs Therapeutics's reading of $2.6M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.